CorMedix Inc. Secures Deal With Leading Dialysis Provider

CorMedix Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol CRMD, recently disclosed a significant development. The company has sealed a multi-year commercial supply agreement with a leading midsized dialysis provider for its therapeutic product, DefenCath® (taurolidine and heparin). This contract marks a crucial step in making DefenCath® widely available to patients.

DefenCath® received New Drug Application (NDA) approval through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023. The commercialization of the product commenced in hospital settings on April 15 of the current year. CorMedix is aiming to extend its reach, with plans to introduce DefenCath® in outpatient dialysis clinics starting in July. This strategic move is part of the company’s commitment to forging substantial long-term partnerships with dialysis providers focused on innovation and infection control. The new agreement will enable access to DefenCath® at over 500 dialysis centers nationwide.

Joseph Todisco, CEO of CorMedix, expressed his satisfaction with the progress made in discussions with outpatient dialysis providers. He emphasized that this agreement will ensure that thousands of patients at risk for catheter-related bloodstream infections can access DefenCath®. Todisco highlighted the company’s ultimate objective: to provide the broadest possible access to this critical infection reduction technology.

CorMedix Inc. specializes in developing and commercializing therapeutic products targeting life-threatening conditions and diseases. Their flagship product, DefenCath®, approved by the FDA in November 2023, is central to their efforts. After its recent inpatient market launch, CorMedix is preparing to introduce the product in outpatient settings by July 2024. The company also has plans to develop DefenCath® as a catheter lock solution suitable for other patient groups.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!